Fractalkine/CX3CL1 Protein, Human (S199N, CHO)

Fractalkine/CX3CL1 Protein, Human (S199N, CHO) is the member of CX3C chemokine family, associated with many cancers and promotes tumor progression.

Fractalkine is the only member of the CX3C chemokine family so far. It is expressed in many cell types such as hematopoietic cells, endothelial cells, epithelial cells, smooth muscle cells, dendritic cells, neurons, and fibroblasts. Fractalkine exists in two forms that have distinct cellular functions. The soluble form is a chemoattractant for cells expressing the CX3CR1 receptor. The membrane-bound form functions as an adhesion molecule that promotes adhesion and migration^[1].

The EC₅₀ is <1.5 µg/mL as measured on Ca²⁺ mobilization assay in CHO-K1/Gα15/hCX3CR1 cells (human Gα15 and hCX3CR1 stably expressed in CHO-K1 cells).

Human

CHO

Tag Free

P78423 (Q25-R339, S199N)

6376  [NCBI]

Extracellular Domain

QHHGVTKCNITCSKMTSKIPVALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGTFEKQIGEVKPRTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTGVTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEAPSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQDWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDAQAATR

Approximately 50-75 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS.

<0.2 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Liu JF, et al. Fractalkine/CX3CL1 induced intercellular adhesion molecule-1-dependent tumor metastasis through the CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma. Oncotarget. 2016 Aug 12;8(33):54136-54148.  [Content Brief]